Diagnostic significance of the newest biomarkers of steatosis progression in patients with stable coronary heart disease, combined with nonalcoholic fatty liver disease

Diagnostic significance of the newest biomarkers of steatosis progression in patients with stable coronary heart disease, combined with nonalcoholic fatty liver disease

The purpose was to determine the diagnostic value of selenoprotein P and M30 fragments of cytokeratin 18 in conjunction with proinflammatory cytokines for early diagnosis and progression of non-alcoholic fatty liver disease (NAFLD) in patients with stable coronary heart disease (CHD). Materials a...

Full description

Saved in:

Bibliographic Details
Main Authors:	I. I. Vakalyuk, N. G. Virstyuk
Format:	Article
Language:	English
Published:	Zaporizhzhia State Medical and Pharmaceutical University 2018-03-01
Series:	Aktualʹnì Pitannâ Farmacevtičnoï ì Medičnoï Nauki ta Praktiki
Subjects:	liver steatosis biomarkers coronary heart disease non-alcoholic fatty liver disease
Online Access:	http://pharmed.zsmu.edu.ua/article/view/123648/119459
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Improvement of non-alcoholic fatty liver disease treatment
by: P. I. Seliverstov, et al.
Published: (2014-10-01)

Adherence to plant based diets reduce the risk of hepatic fibrosis in nonalcoholic fatty liver disease
by: Mahsa Miryan, et al.
Published: (2025-05-01)

Sex-specific effect of dietary fatty acids on non-alcoholic fatty liver disease
by: Jianhua Chen, et al.
Published: (2025-07-01)

The effect of non-alcoholic fatty liver disease on the development of cardiovascular diseases
by: N. A. Starodubtseva, et al.
Published: (2025-03-01)

Reactive Oxygen Species as Key Molecules in the Pathogenesis of Alcoholic Fatty Liver Disease and Nonalcoholic Fatty Liver Disease: Future Perspectives
by: Zhiqing Zhang, et al.
Published: (2025-06-01)

Usefulness of pemafibrate for non-alcoholic fatty liver disease with hypertriglyceridemia
by: Masahiro Kikuchi, et al.
Published: (2024-09-01)

Clinical and Pathogenetic Parallels of Nonalcoholic Fatty Liver Disease and Gallstone Disease
by: Aleksey O. Bueverov
Published: (2019-03-01)

An Effect of Ursodeoxycholic Acid on Inflammation, Steatosis and Liver Fibrosis and Atherogenesis Factors in Patients with Non-Alcoholic Fatty Liver Disease: Results of the USPEH Study
by: M. V. Mayevskaya, et al.
Published: (2020-01-01)

Association of the p.I148m polymorphism in the <i>PNPLA3</i> gene with the severity of nonalcoholic fatty liver disease in various clinical groups
by: D. V. Sidorenko, et al.
Published: (2024-04-01)

Methodical approaches in experimental modelling of non-alcoholic fatty liver disease
by: N. V. Bivalkevich, et al.
Published: (2015-09-01)

MOFI-FL, a novel score for detecting hepatic steatosis and predicting cardiometabolic mortality
by: Juan Reyes-Barrera, et al.
Published: (2025-08-01)

Anthropometric studies of patients with nonalcoholic fatty liver disease
by: K. V. Pivtorak
Published: (2017-10-01)

Predictors of hepatic steatosis in living liver donors
by: M. G. Minina, et al.
Published: (2022-12-01)

Serum β-klotho is a potential biomarker for diagnosing alcoholic liver disease and differentiating from nonalcoholic fatty liver disease
by: Chengmei Fang, et al.
Published: (2025-08-01)

Hepatogenic weakness as a clinical marker of hyperammonemia and of the effectiveness of its correction in patients with pre-cirrhotic stages of non-alcoholic fatty liver disease
by: E. M. Petrova, et al.
Published: (2021-06-01)

PREVALENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE AMONG OBESE PREGNANT WOMEN
by: I. O. Makarov, et al.
Published: (2016-09-01)

PROGNOSTIC SIGNIFICANCE OF GALECTIN-3 MEASUREMENT IN PATIENTS WITH METABOLIC SYNDROME AND NON-ALCOHOLIC FATTY LIVER DISEASE
by: O. M. Drapkina, et al.
Published: (2015-10-01)

Continuum of non-alcoholic fatty liver disease: from hepatic steatosis to cardiovascular risk
by: O. M. Drapkina, et al.
Published: (2016-09-01)

The role of microbiota in nonalcoholic fatty liver disease: mechanism of action and treatment strategy
by: Siwen Shen, et al.
Published: (2025-07-01)

Comparing non-alcoholic fatty liver disease indices in predicting the prevalence and incidence of metabolic syndrome in middle-aged adults
by: Byung Sik Kim, et al.
Published: (2025-03-01)

Diagnostic markers of hepatic steatosis in patients with chronic viral hepatitis C
by: V. V. Tsvetkov, et al.
Published: (2023-05-01)

Alcohol Abstinence Rescues Hepatic Steatosis and Liver Injury via Improving Metabolic Reprogramming in Chronic Alcohol-Fed Mice
by: Aiwen Pi, et al.
Published: (2021-09-01)

Features of Glucose Homeostasis and Blood Lipid Spectrum in Patients with Nonalcoholic Fatty Liver Dis ease Depending on the Obesity Degree
by: Korniichuk I., et al.
Published: (2019-04-01)

Features of nonalcoholic fatty liver disease pharmacotherapy in patients with overweight and obesity
by: K. V. Pivtorak
Published: (2017-08-01)

Nonalcoholic fatty liver disease and atrial fibrillation: the main markers of this association
by: O. B. Teslenko, et al.
Published: (2023-05-01)

The impact of parity on the risk of nonalcoholic fatty liver disease defined by hepatic steatosis index: A nationwide cohort study
by: So-hyeon Hong, et al.
Published: (2025-07-01)

The validity of serum autotaxin as a predictor of hepatic fibrosis in patients with nonalcoholic fatty liver disease
by: Muhammad Abdel-Gawad, et al.
Published: (2023-10-01)

Sodium-glucose cotransporter-2 inhibitors improve liver enzymes in patients with co-existing non-alcoholic fatty liver disease: a systematic review and metanalysis
by: Waseem Amjad, et al.
Published: (2022-01-01)

Metabolic dysfunction‐associated steatotic liver disease: A superior predictor for incident type 2 diabetes over traditional criteria – NAGALA study
by: Kimiko Sakai, et al.
Published: (2024-12-01)

INCIDENTAL HEPATIC STEATOSIS IDENTIFIED ON ULTRASOUND IN PATIENTS UNDERGOING CHOLECYSTECTOMY: HIGH PREVALENCE AND INSUFFICIENT INVESTIGATIVE AND CLINICAL MANAGEMENT
by: Heloísa Mello TRAPP, et al.
Published: (2025-05-01)

The peculiarities of adiponectin and resistin interrelationships with the components of metabolic syndrome in patients with coronary heart disease and concomitant nonalcoholic fatty liver disease
by: N. S. Mykhailovska, et al.
Published: (2016-10-01)

IMMUNOLOGICAL MECHANISMS FOR THE DEVELOPMENT OF NONALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH GOUT AND PSEUDOGOUT: A REVIEW OF LITERATURE
by: D. A. Nabieva
Published: (2017-10-01)

Effects of Aramchol in patients with nonalcoholic fatty liver disease (NAFLD). A systematic review and meta-analysis
by: Adnan Malik, et al.
Published: (2022-02-01)

From adiposity to steatosis: metabolic dysfunction-associated steatotic liver disease, a hepatic expression of metabolic syndrome – current insights and future directions
by: Bruno Basil, et al.
Published: (2024-12-01)

Changes in indicators of fibrosis in patients with alcoholic liver cirrhosis associated with non-alcoholic fatty liver disease depending on the stage of cirrhosis
by: N. R. Matkovska, et al.
Published: (2020-06-01)

Comparison of Transient Elastography and Liver Biopsy in Assessing Fibrosis in Patients with Nonalcoholic Fatty Liver Disease
by: Gaurav Bachhav, et al.
Published: (2021-05-01)

Role of diet and lifestyle modification in the management of nonalcoholic fatty liver disease and type 2 diabetes
by: Orsu Prabhakar, et al.
Published: (2021-01-01)

CORRECTION OF MICROCIRCULATORY DISORDERS IN NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH CHRONIC HEART FAILURE PATIENTS
by: M. E. Statsenko, et al.
Published: (2016-12-01)

The effects of kefir drink on liver aminotransferases and metabolic indicators in patients with nonalcoholic fatty liver disease: a randomized controlled trial
by: Farzaneh Mohammadi, et al.
Published: (2025-01-01)

Ultrasound Score of Liver Steatosis Severity in the Diagnosis of Peripheral Arterial Atherosclerosis in Patients with Nonalcoholic Fatty Liver Disease
by: A. S. Kuznetsova, et al.
Published: (2023-06-01)